Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Commentary on "Biomarkers in Alzheimer's disease drug development." Can't live without 'em.

Literature DB >> 21575868

Commentary on "Biomarkers in Alzheimer's disease drug development." Can't live without 'em.

Paul S Aisen¹.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21575868 PMCID： PMC3116239 DOI： 10.1016/j.jalz.2010.06.006

Source DB: PubMed Journal: Alzheimers Dement ISSN： 1552-5260 Impact factor: 21.566

Keyword Cloud
References

× No keyword cloud information.

11 in total

1. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.

Authors: William J Jagust; Dan Bandy; Kewei Chen; Norman L Foster; Susan M Landau; Chester A Mathis; Julie C Price; Eric M Reiman; Daniel Skovronsky; Robert A Koeppe
Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566

Review 2. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.

Authors: Clifford R Jack; Matt A Bernstein; Bret J Borowski; Jeffrey L Gunter; Nick C Fox; Paul M Thompson; Norbert Schuff; Gunnar Krueger; Ronald J Killiany; Charles S Decarli; Anders M Dale; Owen W Carmichael; Duygu Tosun; Michael W Weiner
Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566

Review 3. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.

Authors: Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner
Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566

4. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.

Authors: Randall J Bateman; Ling Y Munsell; John C Morris; Robert Swarm; Kevin E Yarasheski; David M Holtzman
Journal: Nat Med Date: 2006-06-25 Impact factor: 53.440

5. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors: Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal: Lancet Neurol Date: 2010-02-26 Impact factor: 44.182

6. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

Authors: P S Aisen; D Saumier; R Briand; J Laurin; F Gervais; P Tremblay; D Garceau
Journal: Neurology Date: 2006-11-02 Impact factor: 9.910

7. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Authors: S Salloway; R Sperling; S Gilman; N C Fox; K Blennow; M Raskind; M Sabbagh; L S Honig; R Doody; C H van Dyck; R Mulnard; J Barakos; K M Gregg; E Liu; I Lieberburg; D Schenk; R Black; M Grundman
Journal: Neurology Date: 2009-11-18 Impact factor: 9.910